High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis – real-world data of HCV elimination program in Georgia

Maia Butsashvili (✉ maiabutsashvili@gmail.com)

Clinic NEOLAB

Lia Gvinjilia

CDC Foundation

George Kamkamidze

Health Research Union

David Metreveli

Medical Center Mrcheveli

Shorena Dvali

Infectious Diseases, AIDS and Clinical Immunology Center

Tamar Rukhadze

Clinic Hepa

Amiran Gamkrelidze

National Center for Disease Control and Public Health

Muazzam Nasrullah

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Shaun Shadaker

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Juliette Morgan

Epidemiology, Informatics, Surveillance and Laboratory Branch (EISLB), Division of Global Health Protection (DGHP), Center for Global Health (CGH), CDC

Francisco Averhoff

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Research article

Keywords: HCV, SVR, genotype 3, fibrosis, liver, elimination

Posted Date: December 9th, 2019

DOI: <https://doi.org/10.21203/rs.2.18492/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Research Notes on July 11th, 2020.

See the published version at <https://doi.org/10.1186/s13104-020-05173-4>.

Abstract

Background: In 2015, Georgia launched world's first HCV elimination program. Initially, patients with advanced liver disease were prioritized to receive sofosbuvir-based treatment regimen, as it was the only DAA available for all genotypes. Purpose of the study was to assess real-world data of treatment outcome among patients with HCV GEN3 and advanced liver fibrosis with sofosbuvir-based regimens.

Methods: GEN3 patients enrolled in the program, received sofosbuvir-based regimens, and had outcome data from April 28 through September 30, 2016 were eligible for the study. Demographic and clinical data were analyzed.

Results: A total of 1525 genotype 3 patients were eligible for analysis; most (72.6%) were aged >45 years, majority were males (95.1%), and all (100%) had advanced liver disease (F3 or F4 by METAVIR score based on elastography). Of those who received sofosbuvir/ribavirin (SOF/RBV) for 24 weeks, 449/566 (79.3%) achieved SVR, while 925/959 (96.5%) who received sofosbuvir/pegylated interferon/ribavirin (SOF/PEG/RBV) for 12 weeks achieved SVR ($p<.01$). Among patients with liver cirrhosis (defined as F4) overall cure rate was 85.7% as opposed to 96.4% for those with F3. Females were more likely to be cured (98.7% vs 89.7%; OR=8.54, 95%CI:1.18-61.87). Patients aged 31-45 years had higher likelihood of achieving SVR compared to patients aged 46-60 years (95.7% vs 87.4%; OR=0.32, 95%CI:0.19-0.53). Independent predictors of SVR were treatment with SOF/PEG/RBV (aOR=6.72, 95%CI:4.49-10.06) and lower fibrosis stage (F3) (aOR=4.18, 95%CI:2.64-6.61).

Conclusions: Real-world experience among HCV GEN3 patients with advanced liver fibrosis and treated by sofosbuvir regimen w/o PEGIFN, demonstrated overall high SVR rate.

Background

The World Health Organization (WHO) estimates, globally 71 million people are living with chronic hepatitis C virus (HCV) infection, and 400,000 die annually, mostly from complications of cirrhosis and hepatocellular carcinoma (1). Recently introduced direct-acting antivirals (DAAs) offer an opportunity for curing the vast majority of infected persons, which will reduce the transmission risk and prevalence of HCV in the population.

Georgia has a high burden of HCV infection; a 2015 national serosurvey found that an estimated 5.4% of adults are currently infected with HCV (2). On April 28, 2015, Georgia launched the world's first National HCV Elimination Program that included free of charge treatment with DAAs for all HCV infected persons (3). The DAAs for the elimination program are donated by Gilead Sciences, and sofosbuvir was the first DAA available for the program. In the initial phase of the program, patients with moderate or severe liver disease were prioritized to receive treatment (3). Cure rates for HCV infection (i.e., Sustained Virologic Response or SVR) varies depending on the genotype, degree of liver fibrosis, and the specific DAAs used (4–11). HCV infected patients with genotype 3 are considered difficult to treat with DAAs, compared to other genotypes (5,12,13).

The HCV elimination treatment program in Georgia, with a large number of patients with genotype 3 patients offers a unique opportunity to study the outcomes among these hard to treat patients in a real-world setting. We aimed to study the real-world treatment outcomes among genotype 3 HCV infected patients with advanced disease treated with sofosbuvir (SOF)-based regimens.

Methods

The Georgia National HCV Elimination Program collects data on enrolled patients' pre-treatment, during treatment, and post treatment. Data collected includes socio-demographic information, clinical and laboratory data, and prescribed medications based on national guidelines upon enrolment. These data are collected using standardized protocols, and entered into a national treatment database, STOP-C, developed for the HCV elimination program. Data collected and stored in STOP-C includes HCV genotype and viral load, level of liver fibrosis, risk factors for HCV infection and treatment-related laboratory data, including SVR at week 12–24 after completion of treatment.

Data from April 28, 2015 through September 30, 2016 from STOP-C were analysed. Characteristics and outcomes of patients with genotype 3 were extracted. Only patients with advanced fibrosis (F3 or F4 by METAVIR score based on elastography) who had SOF-based regimens and valid SVR 12–24 results were included in the analysis. The treatment for patients with genotype 3 per national guidelines, was either sofosbuvir and ribavirin (SOF/RBV) for 24 weeks, or sofosbuvir, ribavirin and pegylated interferon (PEG IFN) 2a or 2b (SOF/PEG/RBV) for 12 weeks, depending on patient eligibility to receive IFN. Treatment outcomes were analysed by degree of liver fibrosis (F4-cirrhosis vs F3-non-cirrhosis) and treatment regimen. Statistical software, SAS version 9.4, was used for data analysis. Bivariate associations between treatment outcome with different factors, such as treatment regimen, fibrosis stage, age, and gender were analysed using chi-square. Multivariate analysis with logistic regression was used to estimate odds ratios adjusted for age and gender (aORs) and define independent predictors of SVR.

Results

A total of 1525 genotype 3 patients completed their SOF-based treatment and had an SVR result available for analysis (Table 1). The overall cure rate i.e., SVR for the genotype 3 patients was 90.1% (1374/1525). Among patients with liver cirrhosis (F4 by elastography) the overall cure rate was 85.7% (764/892) as compared to non-cirrhotic patients (F3 or F3/F4) where 610/633 (96.4%) achieved SVR. The SVR rate was significantly higher among those treated with SOF/INF/RBV containing regimen compared to those ineligible for prescribing interferon-based treatment. Out of 959 patients receiving PEG IFN 2a or 2b with SOF and RBV for 12 weeks, 925 (96.5%) achieved SVR compared to 79.3% cure rate among those treated with SOF and RBV for 24 weeks (449 out of 566).

Table 1

Sustained virologic response (SVR) by age, gender and fibrosis stage (N = 1525), nationwide HCV elimination program, Georgia, April 28, 2015–September 30, 2016

	Total n (%) N = 1525	SVR achieved n (%) N = 1374	Unadjusted OR and 95% CI	Adjusted OR and 95% CI
Age group	7	7 (100.00)	–	
18–30	411	393 (95.62)	1	
31–45	986	862 (87.42)	0.32 (0.19, 0.53)	
46–60	121	112 (92.56)	0.57 (0.25, 1.30)	
>60				
Gender	1450	1300 (89.66)	1	
Male	75	74 (98.67)	8.54 (1.18, 61.87)	
Female				
Fibrosis stage	892	764 (85.65)	1	1
F4	633	610 (96.37)	4.44 (2.82, 7.01)	4.18 (2.64, 6.61)
F3 or F3/F4				
Treatment regimen	566	449 (79.33)	1	1
SOF/RBV	959	925 (96.45)	7.09 (4.76, 10.56)	6.72 (4.49, 10.06)
SOF/INF/RBV				

By bivariate analysis, gender was significantly associated with SVR rate. Females (74/75 [98.7%]) were more likely to be cured compared to males 1300/1450 [89.7%]; OR = 8.54, 95% CI:1.18–61.87). Patients aged 31–45 years had higher chance of achieving SVR (95.7% vs 87.4%) compared to patients aged 46–60 years (OR = 0.32, 95% CI:0.19–0.53).

Multivariate analysis showed that the independent predictors of achieving SVR were treatment regimen (patients treated with SOF/IFN/RBV combination were more likely to be cured–aOR = 6.72, 95% CI:4.49–10.06) and fibrosis stage (non-cirrhotic patients having higher chance of SVR–aOR = 4.18, 95% CI:2.64–6.61). (Table 1).

Discussion

In this analysis of the real-world experience among HCV genotype 3 infected patients with advanced liver fibrosis treated with SOF containing regimen with or without pegylated interferon, we found patients achieved overall high SVR rates of > 90%. Patients with liver cirrhosis in our cohort achieved higher SVR rates with this “first generation” DAA compared to previous published reports that enrolled cirrhotic patients with HCV genotype 3 (13,14). Several studies demonstrated SVR rates of 60–70% among those receiving the SOF and RBV 24-week regimen (6,14,15,16,17). The VALENCE trial reported an overall SVR rate of 85% among genotype 3 infected patients receiving the 24-week SOF/RBV regimen (6). In the VALENCE trial, SVR rates at 12-weeks post-treatment (SVR 12) were 91% for the non-cirrhotic group and

68% for the group of study participants with liver cirrhosis, and multivariate analysis identified the presence of liver cirrhosis as a predictor of non-response to treatment (6). Our cohort, which included only those with advanced liver disease, had a similar overall SVR rate as the one reported among patients without cirrhosis in the VALENCE study (90.12% vs 91% SVR rate).

Our report was limited to HCV infected genotype 3 patients with advanced liver disease. Also, the treatment outcomes were limited to two antiviral regimens: SOF/PEG/RBV and SOF/RBV. In June of 2016, sofosbuvir/ledipasvir (SOF/LED) was introduced in Georgia (2) and the treatment guidelines were modified to include this combination DAA, resulting in little to no PEG IFN use for treatment. The Georgia treatment guidelines differ from those of the American Association for the Study of Liver Diseases (AASLD) or The European Association for the Study of the Liver (EASL), providing a unique opportunity to observe population-based outcomes with alternative HCV treatment regimens. These results can inform clinicians and policy makers in countries with a large proportion or burden of HCV genotype 3 infection that may not have access to DAAs or combinations of DAAs that are available in high-income countries of North America and Western Europe.

It is hoped that pan-genotypic regimens will soon be introduced in Georgia, presenting the opportunity to greatly simplify testing and treatment regimens, supporting the realization of HCV Elimination in Georgia by 2020 (18).

Conclusions

In conclusion, high SVR rates can be achieved among patients with HCV genotype 3 and advanced liver fibrosis, particularly among those treated with a 12-week SOF/PEG/RBV regimen. This may inform treatment for HCV infected patients in countries with limited access to newer DAAs.

Abbreviations

HCV – hepatitis C virus

WHO – World Health Organization

DAAs – directly acting antivirals

SVR – sustained viral response

SOF – sofosbuvir

RBV – ribavirin

PEG – pegylated

INF – interferon

aOR – adjusted odds ratio

LED – ledipasvir

AASLD – American Association for the Study of Liver Diseases

EASL – European Association for the Study of the Liver

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The use of trade names is for identification only and does not imply endorsement by the Centres for Disease Control and Prevention.

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of Health Research Union (IRB00009520; IORG005619). Study participants were enrolled in the study after signing informed consent form specially developed for this study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable

Author's contributions

MB was a major contributor in conception, design and writing of the manuscript. LG participated in interpretation of data and revision of the manuscript. GK contributed in analysis and interpretation of data. DM participated in data collection and revision of the manuscript. SD participated in data collection. TR participated in data collection. AG contributed in revision of the manuscript. MN

contributed in conception, design and revision of the manuscript. SS participated in analysis and interpretation of data. JM contributed in revision of the manuscript. FA contributed in conception, design and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Georgia HCV elimination program is conducted under the leadership from the Georgia Ministry of Labor, Health, and Social Affairs [MoLHSA] with strong stakeholder support, including partnership and technical assistance from CDC, and commitment from Gilead Sciences to donate direct-acting antiviral HCV medications (DAAs).

References

1. World Health Organization. Hepatitis C factsheet. No 164. Updated April, 2017.
2. Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, Butsashvili M, et al. [National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016](#). MMWR Morb Mortal Wkly Rep 2016 Oct 21; 65(41):1132-1135.
3. Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, et al. [Launch of a Nationwide Hepatitis C Elimination Program-Georgia, April 2015](#). MMWR Morb Mortal Wkly Rep 2015 Jul 24; 64(28):753-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31; 64(29):806
4. Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World Journal of Gastroenterology 2016; 22(22), 5285–5292.
5. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. [Gut](#) 2015; 64(11):1824-33.
6. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. [Sofosbuvir and ribavirin in HCV genotypes 2 and 3](#). N Engl J Med 2014; 370(21):1993-2001.
7. Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, et al. Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. [World J Gastrointest Pharmacol Ther](#) 2017; 8(2):137-146.
8. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. [Sofosbuvir for previously untreated chronic hepatitis C infection](#). N Engl J Med 2013; 368(20):1878-87.
9. Galán RJ, Cidoncha EC, Martín MF, Rodríguez CC, Almeida CV, Verdugo RM. Antiviral regimen complexity index as an independent predictor of sustained virologic response in

- patients with chronic hepatitis C. [J Manag Care Pharm](#) 2013; 19(6):448-53
10. Parise ER, de Oliveira AC, Conceição RD, Amaral AC, Leite K. [Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.](#) [Braz J Infect Dis](#) 2006; 10(2):78-81.
 11. Im GY, Dieterich DT. Direct-acting antiviral agents in patients with hepatitis C cirrhosis. [Gastroenterol Hepatol \(N Y\)](#) 2012; 8(11):727-65.
 12. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. [Gastroenterology](#) 2014; 146(5):1176-92.
 13. Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? [World Journal of Gastroenterology](#) 2015; 21(42), 12101–12113.
 14. Yang YM, Choi EJ. [Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.](#) [Ther Clin Risk Manag](#) 2017; 13:477-497
 15. Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, et al. [Efficacy of sofosbuvir plus ribavirin in treatment-naïve patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.](#) [Antivir Ther](#) 2016; 21(8):671-678
 16. Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al; BOSON Study Group. [Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.](#) [Gastroenterology](#) 2015; 149(6):1462-70.
 17. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al; POSITRON Study; FUSION Study. [Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.](#) [N Engl J Med](#) 2013; 368(20):1867-77.
 18. Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, Butsashvili M, et al. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination – Georgia, 2015-2016. [MMWR Morb Mortal Wkly Rep](#) 2017 Jul 28; 66(29):773-6.